DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
Why the study?
Does exenatide once weekly improve glycemic control and body weight in patients with type 2 diabetes?
Population
295 patients with type 2 diabetes
Comparison
Exenatide once weekly (2 mg) for 52 weeks vs Exenatide BID for 30 weeks, followed by a switch…
Design
RCT, randomized, open-label
Follow-up
52 weeks
Authors
Discussion
Loading...
Member takes
Implication
Supports prolonged exenatide once weekly use for durable control in type 2 diabetes; extends RCT evidence on long-term glycemic maintenance.
Structured PICO
Does exenatide once weekly improve glycemic control and body weight in patients with type 2 diabetes?
P
Population
295 patients with type 2 diabetes (258 entered the 22-week open-ended assessment phase: n=128 QW-only; n=130 BID-->QW)
I
Intervention
Exenatide once weekly (2 mg) for 52 weeks
C
Comparator
Exenatide BID for 30 weeks, followed by a switch to exenatide once weekly for 22 weeks
O
Outcome
A1C, fasting plasma glucose (FPG), body weight, blood pressure, fasting lipids, safety, and tolerability at 52 weekssurrogate
Exenatide once weekly provides sustained improvements in glycemic control and body weight over 52 weeks in patients with type 2 diabetes.
Cite This Study
Buse et al. (2010) studied this question.